Zenas BioPharma, Inc. (ZBIO)
29.67
+1.41
(+4.99%)
USD |
NASDAQ |
Nov 09, 14:55
Zenas BioPharma Net Income (Quarterly) : -108.92M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -108.92M |
| June 30, 2026 | -111.46M |
| March 31, 2026 | -80.99M |
| December 31, 2025 | -240.44M |
| September 30, 2025 | -51.50M |
| June 30, 2025 | -52.22M |
| March 31, 2025 | -33.57M |
| December 31, 2024 | -52.60M |
| Date | Value |
|---|---|
| September 30, 2024 | -38.61M |
| June 30, 2024 | -37.98M |
| March 31, 2024 | -27.80M |
| December 31, 2023 | -24.59M |
| September 30, 2023 | 35.61M |
| June 30, 2023 | -29.05M |
| March 31, 2023 | -19.10M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 14.16M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.00M |
| Total Expenses (Quarterly) | 118.92M |
| EPS Diluted (Quarterly) | -1.647 |
| Enterprise Value | 1.731B |
| Gross Profit Margin (Quarterly) | 99.96% |
| Profit Margin (Quarterly) | -1.09K% |
| Earnings Yield | -33.84% |
| Normalized Earnings Yield | -23.28 |